🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist




























Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Consolidated Half Yearly Results (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025
Sales46545148424850
Expenses41504846364041
Interest0.110.070.160.090.080.030.10
Operating Profit4.183.682.691.825.767.718.62
OPM %9.176.875.263.7713.7816.0517.26
Other Income0.830.540.631.120.83-0.180.95
Depreciation1.161.441.591.561.932.393.00
Profit Before Tax3.732.701.571.304.595.116.47
Tax %26.5422.5924.8436.9228.9834.4425.19
Net Profit2.742.101.180.813.263.354.84
EPS in Rs

Consolidated Profit Loss (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2023Mar 2024
Sales9999
Expenses9195
Operating Profit7.864.50
OPM %7.924.53
Other Income1.361.75
Interest0.190.25
Depreciation2.603.14
Profit Before Tax6.432.86
Tax %24.8730.52
Net Profit4.831.99
EPS in Rs
Dividend Payout %5.430.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2023Mar 2024
Equity Capital1111
Reserves3045
Borrowings0.131.68
Other Liabilities1414
Total Liabilities5571
Fixed Assets2128
CWIP1.672.60
Investments153.22
Other Assets1737
Total Assets5571

Consolidated Cash Flows (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2023Mar 2024
Cash from Operating Activity0.06-4.41
Cash from Investing Activity0.521.49
Cash from Financing Activity-1.3814
Net Cash Flow-0.8012

Documents

Presentations
Concalls
Reports
Presentations
iconiconicon

Investor Presentation

Q2 FY26

iconiconicon

Investor Presentation

Q4 FY25

iconiconicon

Investor Presentation

Q4 FY24

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

iconiconicon

Investor Presentation

Q4 FY24

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

iconiconicon

Investor Presentation

Q2 FY24

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

iconiconicon

Investor Presentation

Q2 FY24

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

iconiconicon

Investor Presentation

Q2 FY24

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

iconiconicon

Investor Presentation

Q4 FY23

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Showing 1 - 8 of 9

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Vaidya Sane Ayurved Laboratories Ltd

Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) is currently trading at 206.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vaidya Sane Ayurved Laboratories Limited (Madhavbaug) specializes in integrative Ayurvedic healthcare, focusing on disease reversal for cardiac issues, diabetes, hypertension, and obesity through its extensive clinic network and hospitals. Recent half-year financials reflected robust growth, with a 19.48% increase in revenue compared to the prior year, driven by enhanced patient engagement and a strategic shift towards disease reversal programs. Madhavbaug is committed to scaling its operations with substantial plans for hospital capacity expansion and infrastructure augmentation, ensuring wider accessibility to its unique treatment methodologies across India. The international collaboration with Maxura Healthcare in Malaysia positions Madhavbaug to explore global markets, enhancing its brand reach and integrating Ayurvedic therapies into a broader international healthcare paradigm.

Over the past 52 weeks, Vaidya Sane Ayurved Laboratories Ltd has traded between a low of ₹81.10 and a high of ₹335.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of approximately 217.10. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vaidya Sane Ayurved Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 131.53 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 217.10 Cr, Vaidya Sane Ayurved Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vaidya Sane Ayurved Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vaidya Sane Ayurved Laboratories Ltd is 131.53. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.